Last updated: February 15, 2026
Product Overview
NDC 63402-0911 corresponds to Ruosso (rosuvastatin calcium), a generic version of the cholesterol-lowering medication originally marketed as Crestor. Rosuvastatin belongs to the statin class of drugs, prescribed primarily for hyperlipidemia and cardiovascular risk reduction. The drug's patent expired in 2016, leading to increased generic competition.
Market Size and Trends
Global and U.S. Market Size
- The global statins market was valued at approximately $14.2 billion in 2022 and is projected to reach $19.7 billion by 2030, with a CAGR of 4.3% (source: Grand View Research[1]).
- The U.S. region accounts for nearly 45% of the total market, driven by high cardiovascular disease prevalence and established prescribing practices.
Market Penetration of Rosuvastatin
- Rosuvastatin holds about 30% of the U.S. statins market share, second to atorvastatin.
- The drug's utilization remains steady due to its potency and favorable clinical profile.
Key Factors Influencing Market Dynamics
- Patent expiration of branded formulations: The loss of patent exclusivity for branded Rosuvastatin in 2016 facilitated generics entries.
- Growing cardiovascular disease prevalence: Increased diagnosis and screening result in higher prescription volumes.
- Cost sensitivity: Price reductions post-generic entry drive volume increases but limit per-unit revenue growth.
- Competitive landscape: Multiple generic manufacturers have entered, leading to intensified price competition.
Pricing Environment
Historical Pricing Trends
- The average wholesale acquisition cost (AWAC) for brand-name rosuvastatin was approximately $240 for a 30-day supply before patent expiry.
- After the patent expiry in 2016, generic rosuvastatin entered the market with initial prices around $120 per 30-day supply.
- Prices declined further as more generics entered, reaching approximately $30-$40 in 2022 for a 30-day supply (sources: SSR Healthcare[2], GoodRx[3]).
Current Price Range
- Price range for generic rosuvastatin (NDC 63402-0911) varies from $25 to $45 per 30-day supply, depending on pharmacy, formulation strength, and purchasing volume.
- Specialty pharmacies may offer lower net prices via negotiations and discounts.
Projected Price Trends
- Over the next five years, generic rosuvastatin prices are expected to stabilize around $20-$30 per 30-day supply.
- Pricing pressures from market saturation and increased purchasing power of pharmacy benefit managers (PBMs) will limit substantial price increases.
- Marginal price declines may occur as new generics enter and supply chain efficiencies improve.
Market Outlook and Revenue Projections
Current Market Share and Revenue
- Assuming a conservative market share of 25% of the U.S. statins segment.
- With approximately 20 million statin prescriptions annually in the U.S., and 30% attributable to rosuvastatin, around 6 million prescriptions are written per year.
- At an average price of $35 per 30-day supply, annual revenue for the generic version approximates $210 million.
Future Market Growth
- Prescriptions for rosuvastatin are projected to grow at 2-3% annually, driven by rising cardiovascular risk and generic drug substitution.
- Market penetration of lower-cost generics will facilitate volume increases, potentially expanding revenue to over $250 million by 2028.
Risks and Opportunities
- Entry of biosimilars or advanced lipid-lowering therapies could pressure generic demand.
- Patient adherence and prescription brand switching policies influence market volume.
- Price negotiations, insurance formularies, and rebates will impact net revenue and profit margins.
Summary
| Parameter |
Estimated Range / Projection |
| U.S. annual prescriptions (rosuvastatin) |
6 million (current); 7-8 million (2028) |
| Current average wholesale price |
$25 - $45 |
| Estimated annual revenue (2023) |
$210 million |
| Projected price in 2028 |
$20 - $30 for a 30-day supply |
| Projected annual revenue in 2028 |
$250+ million |
Citations:
- Grand View Research, "Statins Market Size, Share & Trends Analysis," 2022.
- SSR Healthcare, "Wholesale Drug Price Data," 2023.
- GoodRx, "Rosuvastatin Prices," 2023.
Key Takeaways
- The market for generic rosuvastatin (NDC 63402-0911) remains competitive with prices stabilizing below $30 per 30-day supply.
- Price declines are limited but steady, reflecting increased market saturation and generic proliferation.
- U.S. prescriptions are expected to grow modestly, supporting revenue stability.
- Competition from newer lipid-lowering therapies and potential biosimilars could alter market dynamics.
- Manufacturers and investors should monitor formulary policies and pricing negotiations that strongly influence margins.
FAQs
1. What factors mainly influence the price of NDC 63402-0911?
Market competition, generic supply volume, pharmacy discounts, and formulary inclusion determine its market price.
2. How does the market for rosuvastatin compare to other statins?
Rosuvastatin’s market share is second after atorvastatin, with higher potency offering a competitive advantage but facing similar generic price pressures.
3. What is the outlook for the drug's revenue over the next five years?
Projected revenues should remain stable or slightly increase, contingent on prescription growth and market competition.
4. How does insurance coverage affect pricing?
Rebates and formulary placement influence net payer prices, potentially lowering patient costs and affecting gross revenue.
5. Are there upcoming regulatory or patent issues that could impact pricing?
Since the patent expired in 2016, new formulations are less likely to impact pricing significantly. However, potential biosimilar or new competitors could influence the market.
